Stock · CONCORDBIO · Healthcare
CONCORDBIO share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for CONCORD BIOTECH LIMITED, refreshed every end-of-day run. A systematic, data-only read on CONCORD BIOTECH LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads CONCORDBIO as constructive with a Crack Score of 82/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where CONCORDBIO stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
67/100Fundamental axis
83/100Money flow
52/100Result pulse · Q4 FY26
39/100Fundamental evidence
net profit -36.98% YoY
profit down at least 20% YoY
revenue -24.15% YoY
result score 39.0/100 (weak)
Valuation and context
P/E 53.6 vs sector median 50.4 (1.06x, 57th pctile)
P/E 1.04x its own ~15m median (51.4)
Red flags
above 200DMA (not a confirmed short-side trend)
profit collapse (-36.98% YoY)
weak filed result (score 39.0)
Relative valuation
P/E (TTM)
53.6P/E vs sector
+1.1%Sector percentile
57PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for CONCORDBIO are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the CONCORDBIO chart, refreshed every end-of-day run.
The Crack Score, and how it is built82 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for CONCORDBIO, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on CONCORDBIO reads right now.
The editorial price read on CONCORDBIO is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on CONCORDBIO can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving CONCORDBIO.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why CONCORDBIO moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
CONCORD BIOTECH LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
39 / 100Revenue
Rs 326 crNet profit
Rs 88 crEPS (quarter)
Rs 8.46| Growth | YoY | QoQ |
|---|---|---|
| Revenue | -24.1% | +17.4% |
| Net profit | -37.0% | +39.0% |
| Net margin | +27.1% | |
Figures are the Q4 FY26 result for CONCORD BIOTECH LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter12 quarters on record
CONCORD BIOTECH LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2023. These are quarterly facts, not TTM valuation inputs.
CONCORDBIO official result trail
12 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 326 cr | Rs 8.46 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 278 cr | Rs 6.08 | n/a | 58/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 247 cr | Rs 6.03 | n/a | 68/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 204 cr | Rs 4.21 | n/a | 58/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 430 cr | Rs 13.42 | n/a | 58/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 244 cr | Rs 7.26 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 310 cr | Rs 9.15 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 216 cr | Rs 5.70 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 319 cr | Rs 9.08 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 241 cr | Rs 7.41 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 262 cr | Rs 7.74 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 195 cr | Rs 5.21 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
CONCORD BIOTECH LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
1,055 crNet profit (TTM)
259 crEBIT (TTM)
342 crProfit before tax (TTM)
342 crNet margin (TTM)
24.6%Finance costs (TTM)
0.3 crBalance sheet, as filed 2026-03-31
Total assets
2,235 crShareholder equity
2,015 crTotal borrowings
0.0 crCash and equivalents
12.2 crInventory
326 crTrade receivables
460 crThe cash engine, latest filed year
Operating cash flow
267 crCapex
95.2 crFree cash flow
172 crInvesting flow
-143 crFinancing flow
-113 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 1,055 cr | 259 cr | 2,015 cr | 0.0 cr | 267 cr |
| FY25 | 1,200 cr | 372 cr | 1,813 cr | 0.4 cr | 245 cr |
| FY24 | 1,017 cr | 308 cr | 1,527 cr | 6.2 cr | 265 cr |
Every figure is parsed from CONCORD BIOTECH LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record12 earnings calls
Every CONCORDBIO earnings call BazaarBaazi has indexed, latest 30 Jun 2026. Read management in its own words, straight from the filed transcript.
CONCORD BIOTECH LIMITED earnings calls on record
12 calls since 30 Sep 2023
Show 4 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from CONCORD BIOTECH LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
CONCORD BIOTECH LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
67 / 100Event Heat is a dated net read of CONCORD BIOTECH LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the CONCORDBIO chart. Not a substitute for a registered research note.
| Ticker | CONCORDBIO |
|---|---|
| Full name | CONCORD BIOTECH LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE338H01029 |
| Market-cap band | ~13,900 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | CONCORDBIO |
Reference chartLevels in show
The daily frame the desk reads on CONCORDBIO.
FAQ11 reader questions · AEO-eligible
The line on CONCORDBIO, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the CONCORDBIO share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on CONCORDBIO. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for CONCORDBIO?
The BazaarBaazi Crack Score for CONCORDBIO is 82 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on CONCORDBIO?
Strike-level option inventory for CONCORDBIO is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is CONCORDBIO in and which peers does BazaarBaazi track?
CONCORDBIO sits in Healthcare (mid cap), indicative market cap ~13,900 cr (indicative), ISIN INE338H01029. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on CONCORD BIOTECH LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the CONCORDBIO view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on CONCORDBIO is bullish, published in Systematic Read on 21 Jul 2026.
Is CONCORDBIO a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, CONCORD BIOTECH LIMITED sits in the Scanned tier with a setup score of 62/100 (technical 67, fundamental 83). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read CONCORD BIOTECH LIMITED's earnings call transcripts?
BazaarBaazi indexes 12 CONCORDBIO earnings calls going back to 2023-09-30, latest 2026-06-30. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was CONCORD BIOTECH LIMITED's Q4 FY26 net profit?
CONCORD BIOTECH LIMITED reported a net profit of Rs 88 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -37.0% year on year. The figure is from the company's official NSE filing.
What was CONCORD BIOTECH LIMITED's Q4 FY26 revenue?
CONCORD BIOTECH LIMITED reported revenue of Rs 326 cr for Q4 FY26. That is -24.1% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate CONCORD BIOTECH LIMITED's Q4 FY26 result?
BazaarBaazi gives CONCORD BIOTECH LIMITED's Q4 FY26 result a Result Pulse of 39 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Concord Biotech Ltd announced recently?
The most recent official filing on record for Concord Biotech Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside CONCORDBIO, each a living view refreshed every end-of-day run.